CN117797172B - 一种抗炎、止血、促愈合的组合体的制备方法 - Google Patents
一种抗炎、止血、促愈合的组合体的制备方法 Download PDFInfo
- Publication number
- CN117797172B CN117797172B CN202410223285.9A CN202410223285A CN117797172B CN 117797172 B CN117797172 B CN 117797172B CN 202410223285 A CN202410223285 A CN 202410223285A CN 117797172 B CN117797172 B CN 117797172B
- Authority
- CN
- China
- Prior art keywords
- powder
- tissue
- healing
- inflammatory
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种抗炎、止血、促愈合的组合体的制备方法,包括将新鲜动物组织制成生物组织膜片,真空冻干并研磨成粉末后与壳聚糖、海藻酸钠粉末混合,制备成组合体粉末;将组合体粉末加入乙酸溶解,搅拌,制备得到组合体凝胶,该组合体粉末或凝胶含天然胶原蛋白,糖胺多糖,细胞因子等活性成分以及多种具有抗炎修复等功能的化学成分,涉及生物医学领域。本发明制备的产品和原料具有生物降解性,生物相容性和功能稳定性,能有效止血,抗炎,促进皮肤修复,预防或治疗瘢痕产生,在医疗大面积烧伤创伤和各种皮肤损伤及白癜风等各种皮肤异常、医美祛痘,修复瘢痕及化妆品领域具有广泛应用前景。
Description
技术领域
本发明涉及生物医学技术领域,具体是指一种抗炎、止血、促愈合的组合体的制备方法。
背景技术
化妆品作为现今人们日常用品,市场需求巨大。传统的抗炎、消痘化妆品治疗效果不明显,且存在成本太高,甚至含激素类产品从而导致过敏、内分泌紊乱、皮肤炎症、色素沉着等问题。研发特效新型化妆品,成为当今市场的热点和难点。
天然生物组织原料含胶原蛋白、弹性蛋白、糖胺多糖、细胞因子等活性成分,其属于生物体内的结构和具有多种生理功能的活性成分等特质,在医疗和医美领域可作为皮肤创伤、抗炎及修复治疗材料,还可作为产品和原料用于特效化妆品。壳聚糖为天然多糖甲壳素脱除部分乙酰基的产物,具有生物降解性、生物相容性、无毒性、抑菌、增强免疫等多种生理功能,广泛应用于食品、美容、化妆品、抗菌剂、医用敷料、人造组织材料、生物医用领域等众多领域。壳聚糖无毒、无味、有抑菌作用,配入化妆品中,可提高产品的成膜性,具有抑菌、保湿功能,又不引起任何过敏刺激反应。海藻酸钠,是一种天然高分子多糖聚合物,具有保湿和促进愈合、抗菌消炎、促进组织修复等功能。由于其具有独特的增稠性、亲水性、稳定性、胶凝性等特性,应用广泛。
皮肤是人体最大的器官,是人体的重要屏障,参与机体体温、代谢、免疫等重要功能。其易因外界各种因素,如烧伤、创伤、炎症等物理和化学因素,及代谢异常,如白癜风等,影响受到损伤。当皮肤缺损和炎症,或代谢异常达到一定面积且难以愈合形成瘢痕时,很难自我修复,需要创面修复手术或药物来促进愈合。长期以来,寻找一种能较快促进创面愈合的理想敷料或凝胶状物质一直是研究热点。现有的创伤类治疗敷料或凝胶多数成分较为单一,愈合速度不够快速。因此,如何选择有效方法和药物,最大限度促进皮肤伤口的愈合修复,止血消炎抗菌,是当前科研领域的一个重要课题。
传统的高压蒸汽灭菌一般是在0.105MPa的压力下,121℃灭菌15~30min,适用于耐高温物品、器械和培养基等,但不适用于粉末和凝胶的灭菌。等离子灭菌利用气体发生电离反应的原理,对不耐热、不耐湿的手术器械等进行灭菌,不适用于液体及粉末的消毒灭菌。环氧乙烷灭菌主要经过真空并加湿,恒温加药后将残气置换的过程,利用其烷基化作用原理抑制生物酶活性,对不能高温灭菌的物品进行熏蒸灭菌,是广谱,高效,穿透力极强,对物品损害轻微的低温灭菌方式。传统环氧乙烷灭菌一般不用于液体和粉剂。
发明内容
本发明的目的在于提供一种抗炎、止血、促愈合的组合体的制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种抗炎、止血、促愈合的组合体的制备方法,包括以下步骤:
S1:获取新鲜的健康动物小肠或膀胱,无菌水冲洗干净后,裁剪至所需的长度,将其制备成组织膜片;
S2:将制备的组织膜片置于真空冷冻干燥机中,-50℃以下,冻干8-14小时;
S3:取出组织膜片,通过研磨设备制成组织粉末一;
S4:取1—3份粉末一,6—12份粉末二,6—12份粉末三制备成组合体粉末,并经环氧乙烷消毒灭菌,小于10℃保存;
粉末二、粉末三为辅料,其能够促进皮肤的愈合;
其中,环氧乙烷灭菌步骤如下:称取适量制备好的粉末放入培养皿中,用医用灭菌纸作为半透膜包裹培养皿,无菌胶带密封好培养皿和医用灭菌纸缝隙,放在环氧乙烷灭菌箱的载物架上,灭菌物品占灭菌室80%空间,放入灭菌指示卡,设置真空负压30-50KPa进行灭菌。
在本发明的一种优选实施方式中,组织膜片的制备,包括以下步骤:
P1:采用新鲜健康动物小肠或膀胱,在无菌条件下置于一次性培养皿中,无菌水冲洗,手工分离去除各层组织,保留其中黏膜下层组织;将黏膜下层组织持续用无菌水冲洗后修剪至所需长度,浸泡于含80—120mmol/L乙二胺四乙酸(EDTA)和8—12mmol/L氢氧化钠(NaOH)的溶液中;
P2:将此黏膜下层组织再次冲洗后浸泡在含0.5—1.5mmol/L盐酸(HCl)和0.5—1.2mmol/L的氯化钠(NaCl)溶液中;
P3:将黏膜下层组织再次冲洗后浸泡在含0.7—1.5mmol/L氯化钠(NaCl)的磷酸缓冲液(PBS)溶液中,此时黏膜下层组织制成了细胞外基质;
P4:将黏膜下层组织取出后在PBS中浸泡;取出后冲洗,消毒灭菌后储存。
在本发明的一种优选实施方式中,粉末二为壳聚糖粉末、粉末三为海藻酸钠粉末。
在本发明的一种优选实施方式中,所述组合体粉末加入30-80ml的1%-3%乙酸溶液,搅拌溶解,制成组合体凝胶,离心消泡后冷藏保存。
在本发明的一种优选实施方式中,所述环氧乙烷灭菌步骤也适用于组合体凝胶。
本发明的有益效果如下:
1.与现有的粉末或凝胶类物质相比,本品作为一种新型天然生物组织化学原料的复合体,其制成的组合体粉末或凝胶制品用于敷料,可加速血液凝固,血小板黏附及凝血酶的生成,其高度的水合性特点,可以与细胞及组织紧密联系,用于医美,化妆品领域可制成各种修复产品,与现有材料相比,本品具有促进皮肤修复,促进炎症消退,预防或淡化瘢痕产生,治疗效果好,本品成本低廉,经济和社会效益更好;
2.该产品在医疗领域可用于烧伤、创伤白癜风、难治性瘢痕等方面病人的皮肤修复,在医美领域可用于促进皮肤各种损伤及愈合祛痘淡斑,以及作为产品和原料用于化妆品领域;
3.本发明采用特殊的包装方式,因医用灭菌纸孔径大于环氧乙烷气体,小于需要灭菌的凝胶或粉末,在30-50KPa压力使用条件下,环氧乙烷气体可以透过灭菌纸进入培养皿内,对凝胶或粉末进行充分消毒。同时,培养皿内凝胶或粉末不会从医用灭菌纸溢出,在灭菌的同时保留了粉末和凝胶的性状和功效不发生改变。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解,其中:
图1为组合体凝胶用于1号受试者后第3—12天的实际效果;
图2为组合体凝胶用于2号受试者后第3—20天的实际效果;
图3为伤口未做愈合处理的裸鼠-对照组,以及伤口使用凝胶的裸鼠-实验组,分别在实验手术切皮后及术后第三天至第十九天的伤口愈合情况及瘢痕生长情况的对照组图;
图4为组合体的粉末成品图;
图5为组合体的凝胶成品图。
具体实施方式
下面详细描述本发明的实施例组合体,所述实施例的示例在附图中示出,其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的,仅用于解释本发明,而不能理解为对本发明的限制。
一种抗炎、止血、促愈合的组合体的制备方法,其包括如下步骤:
S1:获取新鲜的健康动物小肠或膀胱,无菌水冲洗干净后,裁剪至所需的5—15cm的长度,将其制备成组织膜片,组织膜片的制备如下:采用新鲜健康动物小肠或膀胱,在无菌条件下置于一次性培养皿中,无菌水冲洗若干遍后,分离去除各层组织,保留其中黏膜下层组织;将黏膜下层组织持续用无菌水冲洗数次后修剪至2—6cm,浸泡于含80—120mmol/L乙二胺四乙酸(EDTA)和8—12mmol/L氢氧化钠(NaOH)的溶液中10—18小时;
将此黏膜下层组织再次冲洗后浸泡在含0.5—1.5mmol/L盐酸(HCl)和0.5—1.2mmol/L的氯化钠(NaCl)溶液中5—10小时;
将黏膜下层组织再次冲洗后浸泡在含0.7—1.5mmol/L氯化钠(NaCl)的磷酸缓冲液(PBS)溶液中12—18小时,此时黏膜下层组织制成了细胞外基质;
将黏膜下层组织取出后在PBS中浸泡1—3小时;取出后冲洗,消毒灭菌后储存;
S2:将制备的组织膜片置于真空冷冻干燥机中,-50℃以下,冻干8-14小时;
S3:取出冻干完全的膜片组织,通过研磨设备制成组织粉末一;
S4:取1—3份粉末一,6—12份粉末二,6—12份粉末三制备成组合体粉末,粉末二、粉末三为辅料,其能够促进皮肤的愈合,比如粉末二为壳聚糖粉末、粉末三为海藻酸钠粉末;
将粉末一、粉末二、粉末三的组合体粉末置于烧杯,加入30-80ml的1%-3%乙酸溶液,搅拌溶解,制成凝胶,离心消泡后冷藏保存,离心机的参数设置为10000rpm,5min;
具体地,称取0.1—0.3g粉末一,生物组织粉末,0.6—1.2g粉末二,壳聚糖粉末,0.6—1.2g粉末三,海藻酸钠粉末制备成组合体粉末置于烧杯;加入30—80ml的1%-3%乙酸溶液,用搅拌仪搅拌溶解,大约0.5—2小时制成凝胶后环氧乙烷消毒,密闭封装;
将组合体粉末制备成凝胶,组合体粉末和凝胶经环氧乙烷消毒灭菌,灭菌步骤如下:称取适量制备好的粉末或凝胶放入培养皿中,用半透膜密封后放在环氧乙烷灭菌箱的载物架上,放入灭菌指示卡,设置真空负压30KPa进行灭菌;半透膜为医用灭菌纸,其能够让环氧乙烷气体进入到培养皿中灭菌,同时防止组合体粉末受负压吸引从培养皿中脱出。
实例1:
参考图1,每日基础清洁后,将制备的凝胶均匀涂抹于一号受试者的左右两侧的下颌处,分别于第3天,第8天,第12天观察面部皮肤情况,如图1所示,在涂抹凝胶之前,受试者面部的痤疮较为明显,并且有一定的肿胀发红,痘印较多。在使用第3天时,红肿程度有所改善,痘印开始减少,在使用第5天时,红肿开始消退,痘印已经明显减少,皮肤状况明显改善,在使用第7天时,红肿完全消退,痘印基本消退,面部皮肤基本恢复平整,颜色较为均匀。
实例2:
参考图,2每日基础清洁后,将制备的凝胶均匀涂抹于二号受试者的前额处,分别于第3天、第7天、第20天观察前额皮肤情况,如图2所示,在涂抹凝胶之前,受试者前额处的痤疮较为严重,痘印明显,涂抹凝胶第3天时,痤疮红肿程度有所改善,痘印数量有所减少,涂抹凝胶第7天时,痘印已基本消退;涂抹凝胶第20天,前额皮肤已无红肿,痘印基本消退,皮肤平整度改善明显,皮肤颜色恢复均匀。
实例3:
参考图3,将裸鼠分为两组,用10%的水合氯醛麻醉(0.35mL/100g),碘伏消毒后用镊子夹起背部中央皮肤,用组织剪减去直径大小为1cm的圆形皮肤,暴露皮下组织,两组裸鼠分为伤口未做处理组-对照组,和伤口使用凝胶处理组-实验组,对照组裸鼠背部伤口直接清创并用弹力绷带包裹无菌纱布包扎,定期对伤口进行消毒和更换敷料;实验组裸鼠背部伤口涂抹本发明的组合体凝胶,用弹力绷带包裹无菌纱布后包扎,定期对伤口进行消毒和更换敷料;可以观察到,对照组裸鼠背部伤口处在术后第3天时发现瘢痕;术后第7天时伤口瘢痕增加;术后第11天,伤口瘢痕增加并布满伤口外缘,皮肤缺损恢复较差,愈合缓慢;实验组裸鼠术后第10天背部皮肤伤口愈合明显,无瘢痕;第14天,伤口基本愈合;至19天时已基本愈合,未发现瘢痕。
该产品主要成分包括胶原蛋白,弹性蛋白,糖胺多糖,细胞因子等活性成分以及含有多种抗炎修复等功能的天然化学成分,该产品具有生物降解性,生物相容性和功能稳定性,可有效止血,抗炎,促进皮肤修复,预防或治疗瘢痕产生,应用效果好,在医疗大面积烧伤创伤和各种皮肤损伤及白癜风等各种皮肤异常、医美祛痘,修复瘢痕及化妆品领域具有广泛应用前景,本抗炎、止血、促愈合的组合体粉末和凝胶制品重要成分来源于天然的动物组织,利用其来源于生物体内的结构材料和具有多种生理功能的特点,并添加天然化学原料,具有生物降解性和生物相容性,且有功能稳定性和成膜性,可以抗炎、促进代谢,加速皮肤修复,预防或淡化瘢痕产生,应用效果好,在医疗和医美领域可作为皮肤创伤大面积烧伤创伤,整形皮肤愈合,白癜风,难治性瘢痕等所有急慢性皮肤损伤的抗炎及修复治疗材料,还可作为产品和原料用于特效化妆品祛痘,祛斑,护肤制备。
尽管已经示出和描述了本发明的实施例,本领域的普通技术人员可以理解:在不脱离本发明的原理和宗旨的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由权利要求及其等同物限定。
Claims (5)
1.一种抗炎、止血、促愈合的组合体的制备方法,其特征在于,包括以下步骤:
S1:获取新鲜的健康动物小肠或膀胱,无菌水冲洗干净后,裁剪至所需的长度,将其制备成组织膜片;
S2:将制备的组织膜片置于真空冷冻干燥机中,-50°C以下,冻干8-14小时;
S3:取出组织膜片,通过研磨设备制成组织粉末一;
S4:取1—3份粉末一,6—12份粉末二,6—12份粉末三制备成组合体粉末,并经环氧乙烷消毒灭菌,小于10°C保存;
粉末二、粉末三为辅料,其能够促进皮肤的愈合;
其中,环氧乙烷灭菌步骤如下:称取适量制备好的粉末放入培养皿中,用医用灭菌纸作为半透膜包裹培养皿,无菌胶带密封好培养皿和医用灭菌纸缝隙,放在环氧乙烷灭菌箱的载物架上,灭菌物品占灭菌室80%空间,放入灭菌指示卡,设置真空负压30-50KPa进行灭菌;
在S1中,所述的组织膜片的制备,包括以下步骤:
P1:采用新鲜健康动物小肠或膀胱,在无菌条件下置于一次性培养皿中,无菌水冲洗,手工分离去除各层组织,保留其中黏膜下层组织;将黏膜下层组织持续用无菌水冲洗后修剪至所需长度,浸泡于含80—120mmol/L乙二胺四乙酸(EDTA)和8—12mmol/L氢氧化钠(NaOH)的溶液中;
P2:将此黏膜下层组织再次冲洗后浸泡在含0.5—1.5mmol/L盐酸(HCl)和0.5—1.2mmol/L的氯化钠(NaCl)溶液中;
P3:将黏膜下层组织再次冲洗后浸泡在含0.7—1.5mmol/L氯化钠(NaCl)的磷酸缓冲液(PBS)溶液中,此时黏膜下层组织制成了细胞外基质;
P4:将黏膜下层组织取出后在PBS中浸泡;取出后冲洗,消毒灭菌后储存。
2.根据权利要求1所述的一种抗炎、止血、促愈合的组合体的制备方法,其特征在于:粉末二为壳聚糖粉末、粉末三为海藻酸钠粉末。
3.根据权利要求1所述的一种抗炎、止血、促愈合的组合体的制备方法,其特征在于,所述组合体粉末加入30-80ml的1%-3%乙酸溶液,搅拌溶解,制成组合体凝胶,离心消泡后冷藏保存。
4.根据权利要求3所述的一种抗炎、止血、促愈合的组合体的制备方法,其特征在于,所述环氧乙烷灭菌步骤也适用于组合体凝胶。
5.一种抗炎、止血、促愈合的组合体,其特征在于:该组合体由权利要求1-4任一项所述的制备方法制得,是粉末或凝胶形态。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410223285.9A CN117797172B (zh) | 2024-02-28 | 2024-02-28 | 一种抗炎、止血、促愈合的组合体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410223285.9A CN117797172B (zh) | 2024-02-28 | 2024-02-28 | 一种抗炎、止血、促愈合的组合体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117797172A CN117797172A (zh) | 2024-04-02 |
CN117797172B true CN117797172B (zh) | 2024-05-14 |
Family
ID=90423793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410223285.9A Active CN117797172B (zh) | 2024-02-28 | 2024-02-28 | 一种抗炎、止血、促愈合的组合体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117797172B (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007044026A2 (en) * | 2004-11-23 | 2007-04-19 | The Johns Hopkins University | Compositions comprising modified collagen and uses therefore |
CN101361989A (zh) * | 2008-09-03 | 2009-02-11 | 陕西瑞盛生物科技有限公司 | 双层膜状组织修补材料及其制备方法 |
WO2009091549A1 (en) * | 2008-01-14 | 2009-07-23 | Starch Medical Inc. | Modified starch material of biocompatible hemostasis |
CN102120033A (zh) * | 2011-03-07 | 2011-07-13 | 温州医学院 | 促口腔额面部多种创伤修复的复合生长因子的胶原蛋白缓释载体材料及其制备方法 |
CN105999410A (zh) * | 2016-05-05 | 2016-10-12 | 广州昕生医学材料有限公司 | 脱细胞组织基质复合材料及其制备方法 |
CN109513037A (zh) * | 2018-11-14 | 2019-03-26 | 华中科技大学同济医学院附属协和医院 | 一种负载介孔生物玻璃的小肠粘膜下层创面敷料 |
CN109529120A (zh) * | 2018-11-30 | 2019-03-29 | 广州新诚生物科技有限公司 | 一种小肠黏膜下层基质修复凝胶的制备方法 |
CN112121065A (zh) * | 2020-10-09 | 2020-12-25 | 重庆医科大学附属口腔医院 | 医用止血粉及其用途 |
CN113289063A (zh) * | 2021-05-27 | 2021-08-24 | 江阴市人民医院 | 一种软组织修复生物材料及其制备方法 |
CN113456675A (zh) * | 2021-07-26 | 2021-10-01 | 山东大学齐鲁医院 | 脱细胞sis在抑制青光眼术后瘢痕组织增生中的应用 |
CN113727740A (zh) * | 2019-02-26 | 2021-11-30 | 重庆医科大学附属口腔医院 | 医用黏合剂及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8277837B2 (en) * | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
US20090062233A1 (en) * | 2007-08-09 | 2009-03-05 | Xin Ji | Modified starch material of biocompatible hemostasis |
-
2024
- 2024-02-28 CN CN202410223285.9A patent/CN117797172B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007044026A2 (en) * | 2004-11-23 | 2007-04-19 | The Johns Hopkins University | Compositions comprising modified collagen and uses therefore |
WO2009091549A1 (en) * | 2008-01-14 | 2009-07-23 | Starch Medical Inc. | Modified starch material of biocompatible hemostasis |
CN101361989A (zh) * | 2008-09-03 | 2009-02-11 | 陕西瑞盛生物科技有限公司 | 双层膜状组织修补材料及其制备方法 |
CN102120033A (zh) * | 2011-03-07 | 2011-07-13 | 温州医学院 | 促口腔额面部多种创伤修复的复合生长因子的胶原蛋白缓释载体材料及其制备方法 |
CN105999410A (zh) * | 2016-05-05 | 2016-10-12 | 广州昕生医学材料有限公司 | 脱细胞组织基质复合材料及其制备方法 |
CN109513037A (zh) * | 2018-11-14 | 2019-03-26 | 华中科技大学同济医学院附属协和医院 | 一种负载介孔生物玻璃的小肠粘膜下层创面敷料 |
CN109529120A (zh) * | 2018-11-30 | 2019-03-29 | 广州新诚生物科技有限公司 | 一种小肠黏膜下层基质修复凝胶的制备方法 |
CN113727740A (zh) * | 2019-02-26 | 2021-11-30 | 重庆医科大学附属口腔医院 | 医用黏合剂及其制备方法和用途 |
CN112121065A (zh) * | 2020-10-09 | 2020-12-25 | 重庆医科大学附属口腔医院 | 医用止血粉及其用途 |
CN113289063A (zh) * | 2021-05-27 | 2021-08-24 | 江阴市人民医院 | 一种软组织修复生物材料及其制备方法 |
CN113456675A (zh) * | 2021-07-26 | 2021-10-01 | 山东大学齐鲁医院 | 脱细胞sis在抑制青光眼术后瘢痕组织增生中的应用 |
Non-Patent Citations (2)
Title |
---|
人胎十二指肠神经肽分布和发育的研究;陈晓宇等;《安徽医科大学学报》;20021231;第37卷(第6期);第426-428页 * |
小肠黏膜下层冷冻凝胶用于细胞移植支架的研究;廖建贵等;《第三军医大学学报》;20160531;第38卷(第10期);第1060-1065页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117797172A (zh) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jones et al. | Hydrogel dressings in the management of a variety of wound types: A review | |
US4414202A (en) | Composition for treatment of wounds | |
CN101678036B (zh) | 瘢痕生成中的新型活性物质和其用途 | |
US4778679A (en) | Method and composition for treatment of wounds | |
CN105194719A (zh) | 一种面部创口修复敷料、敷贴及其制备方法 | |
CN109432481A (zh) | 一种止血抗菌的聚氨酯敷料及其制备方法 | |
CN104258456B (zh) | 一种含六方介孔硅的创面修复凝胶及其制备方法 | |
CN108478846A (zh) | 一种医用止血抗菌敷料及其制备方法 | |
CN1994481A (zh) | 一种新型高效中药-壳聚糖复合止血材料 | |
CN105056285A (zh) | 一种可粘合组织裂隙的生长因子复合敷料及其制备方法 | |
JP6807922B2 (ja) | 止血、組織障壁、創傷治癒、および美容術のための生体適合性カルボキシメチルセルロースマトリックス(bcm) | |
US20050181025A1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
CN113041391A (zh) | 一种含积雪草-胶原蛋白修复冻干海绵及其制备方法 | |
CN110935056A (zh) | 一种高吸湿性藻酸盐敷料制备方法 | |
CN104474573A (zh) | 一种生物敷膜及制备方法 | |
Sikka et al. | Modern developments in burn wound dressing | |
CN117797172B (zh) | 一种抗炎、止血、促愈合的组合体的制备方法 | |
Cai et al. | [Retracted] Analysis of the Curative Effect and Influencing Factors of Collagen Sponge Combined with Autologous Skin Graft in the Treatment of Deep Burn Patients | |
CN101797376A (zh) | 改性胶原蛋白膜的制备方法 | |
CN111012944A (zh) | 一种基于藻酸盐和透明质酸的液体敷料及其制备方法 | |
EP0034504B1 (en) | Combinations for the treatment of wounds | |
CN100502953C (zh) | 创面活性修复材料 | |
King | Catrix: an easy-to-use collagen treatment for wound healing | |
Price et al. | Skin repair technology | |
CN215080873U (zh) | 立体贴合创面的敷贴 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |